Reports
- Methodological Overview. (Phase 1)
Rosemary Hipkins - Research Report no. 1.
- Research Strategies to
Facilitate Public Participation in Discussion of
Genetic Testing and Bio banking:
A Summary. -
Rosemary Hipkins and Rosemary Du Plessis - Research Report no. 2.
- The Social, Cultural, Ethical
and Spiritual Implications
of Genetic Testing:
Preliminary findings.
Rosemary Du Plesis, Anne Scott and Te Kopere Team: Hazel Phillips, Fiona Cram, Bevan Tipene-Matua, Murry Parsons and Trina Taupo - Research Report no. 3
- Eliciting Complementary
Expertise on Genetic Testing in
Aotearoa New Zealand:
Working paper
Joanna Goven - Research Report no. 4.
- Balancing Risks: The Framing of Human Genetics in Online News Media
Jennifer Molina - Research Report no. 5
- Genetic Privacy
Issues in
Aotearoa/New Zealand.
Jennifer Molina - Research Report no. 6 - Talking About
Genetic Testing:
Information for participants
Research Report no. 7
- Implicaitons of Genetic
Testing for the
Workplace and ACC
Joanna Goven - Research Report no. 8
- Super Salmon: The Industralisation of Aquaculture and the Drive towards GM Technologies in Salmon Production
Carmen McLeod, Janet Grice, Hugh Campbell and Teresa Herleth. Co-funded with the Fate of Biotechnology research project. - Research report no. 9.
- Preliminary Economic Evaluation of Biopharming in New Zealand.
William Kaye-Blake, Caroline Saunders and Louise Ferguson. - Research Report no. 10.
- Biobanking in Aotearoa: A Case Study of the New Zealand Rare Disease Biobank Operated by the NZ Institute for Rare Disease Research Ltd
Rosemary Du Plessis - Research Report no.11.
- Animal Biopharming in New Zealand: Drivers, Scenarios and Practical Implications.
Joanna Goven, Lesley Hunt, David Shamy and Jack A. Heinemann. - Research Report no.12.
- Containing the Sea: the Implications of Biopharming in New Zealand Aquaculture
Hugh Campbell, Angela Mackenzie and Joanna Goven - Research Report No. 13
- Potential Impacts of Biopharming on New Zealand: Results from the Lincoln Trade and Environment Model
William Kaye-Blake, Caroline Saunders and Mariana de Aragão Pereira - Research Report No. 14
- Human Lactoferrin Biopharming in New Zealand: Scientific Risk Assessement
Jack A. Heinemann - Research Report No. 15 - Balancing potential health benefits with cultural concerns: collective and individual decision-making processes regarding the use of Maori genetic material
Bevan Tipene-Matua and Annabel Ahuriri-Driscoll - Research Report No 16 - Nutrigenomics and Public Engagement: An "upstream" inquiry
Joanna Goven and Jack A. Heinemann - Research Report No 17 - Assessing Plant Biopharming in New Zealand: Knowledge from the arable sector
Carolyn Morris, Joanna Goven, Lesley M. Hunt and Jack A. Heinemann - Research Report No 18 -
Biopharming in New Zealand: Risk and Governance Implications
Joanna Goven, Hugh Campbell, Fiona Cram, Jack A. Heinemann, Angela Mackenzie, Carolyn Morris, and Hazel Phillips Research - Report No. 19